Integrase Inhibitor Combination Therapy for Drug-Resistant HIV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing HIV therapeutic agents face challenges with side effects and the emergence of drug-resistant viruses, necessitating the development of a pharmaceutical agent with a different mechanism of action to effectively treat and prevent HIV infections, including strains resistant to current drugs.
Innovation Solution
A pharmaceutical agent combining a compound with HIV-1 integrase inhibiting activity and at least one compound with anti-HIV activity, such as polymerase inhibitors, ribonuclease H inhibitors, or protease inhibitors, to provide a synergistic effect against drug-resistant HIV strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing HIV therapeutic agents (reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors) are used, then anti-HIV efficacy is achieved, but side effects and drug-resistant virus emergence occur
Solution Approach 1:
The patent segments the anti-HIV treatment into multiple distinct mechanisms by combining an integrase inhibitor (compound of formula 1) with at least one other anti-HIV agent having a different mechanism of action. This segmentation allows each component to target different viral processes, reducing the likelihood of cross-resistance and maintaining efficacy against drug-resistant strains.
Solution Approach 2:
The patent creates a composite pharmaceutical formulation combining compounds with different anti-HIV mechanisms of action. The compound of formula (1) (integrase inhibitor) is combined with other anti-HIV agents (polymerase inhibitors, ribonuclease H inhibitors, or protease inhibitors) to form a composite therapeutic agent that leverages multiple mechanisms simultaneously, thereby overcoming drug resistance while maintaining anti-HIV efficacy.
2Reliability
If combination antiretroviral therapies (cART) with 2 to 4 types of anti-HIV agents are administered, then anti-HIV efficacy and prognosis are dramatically improved, but cross-resistance and additive effects limitations occur
Solution Approach 1:
The patent changes the key parameter of mechanism diversity by selecting anti-HIV agents with fundamentally different mechanisms of action. The compound of formula (1) inhibits integrase, while the combined agent targets polymerase, ribonuclease H, or protease. This parameter change ensures that when one mechanism develops resistance, other mechanisms remain effective, thereby improving adaptability against drug-resistant strains.
Data Source
AI summary
A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)— or the like: each R1 independently represents a halogen atom or the like: each of R2a and R2b independently represents a hydrogen atom or the like: R3 represents an alkyl group or a haloalky 1 group: R4 represents a hydrogen atom or an alkyl group: and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof, and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.